About Vir Biotechnology
Vir Biotechnology is a company based in San Francisco (United States) founded in 2017 by Klaus Frueh.. Vir Biotechnology has raised $216 million across 4 funding rounds from investors including Gates Foundation, Arch Venture Partners and GSK. The company has 408 employees as of December 31, 2024. Vir Biotechnology has completed 2 acquisitions, including Agenovir and TomegaVax. Vir Biotechnology offers products and services including Antibody Platform and PRO-XTEN™ Masking Technology. Vir Biotechnology operates in a competitive market with competitors including BeiGene, Serum Institute of India, Vaxcyte, BioNTech and Biological E, among others.
- Headquarter San Francisco, United States
- Employees 408 as on 31 Dec, 2024
- Founders Klaus Frueh
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vir Biotechnology, Inc.
-
Annual Revenue
$74.2 M-13.9as on Dec 31, 2024
-
Net Profit
$-521.96 M15.14as on Dec 31, 2024
-
EBITDA
$-508.86 M20.68as on Dec 31, 2024
-
Total Equity Funding
$216 M (USD)
in 4 rounds
-
Latest Funding Round
$32.44 M (USD), Post-IPO
May 06, 2020
-
Investors
Gates Foundation
& 2 more
-
Employee Count
408
as on Dec 31, 2024
-
Investments & Acquisitions
Agenovir
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vir Biotechnology
Vir Biotechnology is a publicly listed company on the NASDAQ with ticker symbol VIR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Vir Biotechnology
Vir Biotechnology offers a comprehensive portfolio of products and services, including Antibody Platform and PRO-XTEN™ Masking Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for discovering and optimizing antibody-based medicines for diseases.
Technology for masking and releasing treatments in infectious diseases and cancer.
Unlock access to complete
Unlock access to complete
Leadership Team
45 people
Operations Team
11 people
Software Development Team
8 people
Senior Team
8 people
Finance and Accounting
6 people
Product Management Team
3 people
Human Resources and Administration
2 people
Sales and Marketing
2 people
Unlock access to complete
Funding Insights of Vir Biotechnology
Vir Biotechnology has successfully raised a total of $216M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $32.44 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $32.4M
-
First Round
First Round
(26 Sep 2017)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Post-IPO - Vir Biotechnology | Valuation |
investors |
|
| Apr, 2020 | Amount | Post-IPO - Vir Biotechnology | Valuation |
investors |
|
| Jun, 2018 | Amount | Series A - Vir Biotechnology | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vir Biotechnology
Vir Biotechnology has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Arch Venture Partners and GSK. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
Founded Year | Domain | Location | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vir Biotechnology
Vir Biotechnology has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Agenovir and TomegaVax. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Antiviral therapeutics are developed using nuclease-based technologies for infectious diseases.
|
2014 | ||||
|
Developing cytomegalovirus-vector based vaccines for viral infections
|
2011 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Vir Biotechnology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vir Biotechnology Comparisons
Competitors of Vir Biotechnology
Vir Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Serum Institute of India, Vaxcyte, BioNTech and Biological E, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vir Biotechnology
Frequently Asked Questions about Vir Biotechnology
When was Vir Biotechnology founded?
Vir Biotechnology was founded in 2017.
Where is Vir Biotechnology located?
Vir Biotechnology is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Vir Biotechnology?
George Scangos is the current CEO of Vir Biotechnology.
Is Vir Biotechnology a funded company?
Vir Biotechnology is a funded company, having raised a total of $216M across 4 funding rounds to date. The company's 1st funding round was a Series A of $66M, raised on Sep 26, 2017.
How many employees does Vir Biotechnology have?
As of Dec 31, 2024, the latest employee count at Vir Biotechnology is 408.
What is the annual revenue of Vir Biotechnology?
Annual revenue of Vir Biotechnology is $74.2M as on Dec 31, 2024.
What does Vir Biotechnology do?
Developer of therapeutics for the treatment of infectious diseases. The companys approach is focused on immune programming to manipulate pathogen-host interactions. The company has developed drugs for Covid-19, HBV, HIV, and influenza-A.
Who are the top competitors of Vir Biotechnology?
What products or services does Vir Biotechnology offer?
Vir Biotechnology offers Antibody Platform and PRO-XTEN™ Masking Technology.
Is Vir Biotechnology publicly traded?
Yes, Vir Biotechnology is publicly traded on NASDAQ under the ticker symbol VIR.
How many acquisitions has Vir Biotechnology made?
Who are Vir Biotechnology's investors?
Vir Biotechnology has 3 investors. Key investors include Gates Foundation, Arch Venture Partners, and GSK.
What is Vir Biotechnology's ticker symbol?
The ticker symbol of Vir Biotechnology is VIR on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.